OR WAIT 15 SECS
INC Research formally launched the first Site Advocacy Group (SAG), initially focused on central nervous system (CNS) protocols.
INC Research formally launched the first Site Advocacy Group (SAG), initially focused on central nervous system (CNS) protocols. Since first announcing their expanded relationship with SCRS in December, INC has been working to create the SAG and officially launched it last week with a kickoff meeting at their Austin, Texas location, which serves as a primary hub for INC’s CNS clinical trials work.
A recent study by the Tufts Center for the Study of Drug Development found that drugs to treat CNS diseases, such as epilepsy, Alzheimer’s, autism, schizophrenia and depression, take 35 percent longer to develop than other drugs. Progress can be difficult to quantify with these diseases, making it even more critical for investigators and site staff to follow protocols consistently. Members of INC Research’s scientific and operational SAG specialize in psychiatry, with at least 10 years’ experience in schizophrenia, ADHD, depression and/or bipolar disorder, and have five years’ experience as a principal investigator. The group will be involved on an ongoing basis in reviewing protocols and providing feedback and solutions to enhance the conduct of psychiatry studies.